secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001193125-24-273985
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan reports positive Phase 1 ALLOHA data; plans registrational trial for TSC-101 in H2 2025
--------------------------------------------------------------------------------

- Event-free survival strongly favored treatment arm (HR=0.30, p=0.04); relapse probability trended lower (HR=0.28, p=0.14).
- 2 of 26 (8%) treatment-arm patients relapsed vs 4 of 12 (33%) controls; median time to relapse not evaluable vs 160 days.
- No TP53-mutated patients relapsed in treatment arm (0/4 infused), while both control-arm TP53 patients relapsed within 6 months and died.
- Registrational trial for TSC-101 planned for H2 2025 with RFS primary endpoint, powered at HR 0.60, 85% power, ~140 treatment subjects.
- Solid tumor program: 8 patients infused singleplex; first T-Plex product manufactured; IND for MAGE-A4 TCR submitted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/0001193125-24-273985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312524273985/d917413d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-273985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer